Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.03
RDNT's Cash-to-Debt is ranked lower than
97% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. RDNT: 0.03 )
Ranked among companies with meaningful Cash-to-Debt only.
RDNT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.08
Current: 0.03
0
0.08
Equity-to-Asset 0.06
RDNT's Equity-to-Asset is ranked lower than
90% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. RDNT: 0.06 )
Ranked among companies with meaningful Equity-to-Asset only.
RDNT' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.89  Med: -0.24 Max: 0.06
Current: 0.06
-0.89
0.06
Interest Coverage 0.89
RDNT's Interest Coverage is ranked lower than
96% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.49 vs. RDNT: 0.89 )
Ranked among companies with meaningful Interest Coverage only.
RDNT' s Interest Coverage Range Over the Past 10 Years
Min: 0.48  Med: 0.88 Max: 1.25
Current: 0.89
0.48
1.25
Piotroski F-Score: 4
Altman Z-Score: 1.31
Beneish M-Score: -3.43
WACC vs ROIC
6.45%
3.52%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 4.35
RDNT's Operating Margin % is ranked higher than
52% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. RDNT: 4.35 )
Ranked among companies with meaningful Operating Margin % only.
RDNT' s Operating Margin % Range Over the Past 10 Years
Min: 4.35  Med: 6.6 Max: 8.66
Current: 4.35
4.35
8.66
Net Margin % 0.82
RDNT's Net Margin % is ranked higher than
51% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. RDNT: 0.82 )
Ranked among companies with meaningful Net Margin % only.
RDNT' s Net Margin % Range Over the Past 10 Years
Min: -4.26  Med: 0.25 Max: 9.25
Current: 0.82
-4.26
9.25
ROE % 19.60
RDNT's ROE % is ranked higher than
85% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. RDNT: 19.60 )
Ranked among companies with meaningful ROE % only.
RDNT' s ROE % Range Over the Past 10 Years
Min: 17.84  Med: 40.64 Max: 52.1
Current: 19.6
17.84
52.1
ROA % 0.86
RDNT's ROA % is ranked higher than
56% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. RDNT: 0.86 )
Ranked among companies with meaningful ROA % only.
RDNT' s ROA % Range Over the Past 10 Years
Min: -6.42  Med: 0.25 Max: 9
Current: 0.86
-6.42
9
ROC (Joel Greenblatt) % 15.86
RDNT's ROC (Joel Greenblatt) % is ranked higher than
59% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. RDNT: 15.86 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
RDNT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 14.13  Med: 17.94 Max: 25.77
Current: 15.86
14.13
25.77
3-Year Revenue Growth Rate 2.40
RDNT's 3-Year Revenue Growth Rate is ranked lower than
60% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. RDNT: 2.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
RDNT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 2.4  Med: 8.6 Max: 25.5
Current: 2.4
2.4
25.5
3-Year EBITDA Growth Rate -1.80
RDNT's 3-Year EBITDA Growth Rate is ranked lower than
57% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. RDNT: -1.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
RDNT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -43  Med: 6.6 Max: 174
Current: -1.8
-43
174
3-Year EPS without NRI Growth Rate 44.20
RDNT's 3-Year EPS without NRI Growth Rate is ranked higher than
91% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. RDNT: 44.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
RDNT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -51.8  Med: -14.2 Max: 44.2
Current: 44.2
-51.8
44.2
GuruFocus has detected 6 Warning Signs with RadNet Inc $RDNT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RDNT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

RDNT Guru Trades in Q1 2016

Jim Simons 208,700 sh (+15.05%)
» More
Q2 2016

RDNT Guru Trades in Q2 2016

Jim Simons 293,700 sh (+40.73%)
» More
Q3 2016

RDNT Guru Trades in Q3 2016

Jim Simons 434,400 sh (+47.91%)
» More
Q4 2016

RDNT Guru Trades in Q4 2016

Jim Simons 570,101 sh (+31.24%)
» More
» Details

Insider Trades

Latest Guru Trades with RDNT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621491    SIC: 8071
Compare:NAS:MGEN, NAS:ONVO, NAS:SRDX, NAS:TRIB, NAS:QTNT, NAS:OXFD, NAS:PACB, OTCPK:CLIFF, NAS:FLGT, OTCPK:CBIS, NAS:NVDQ, NYSE:ENZ, OTCPK:EPGNF, AMEX:SENS, NAS:TTOO, NAS:CTSO, NAS:FLDM, NAS:AIQ, NAS:VRML, NYSE:NVTA » details
Traded in other countries:PQIA.Germany,
Headquarter Location:USA
RadNet Inc is a provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, and among others.

RadNet Inc is incorporated in Delaware and has been in business since 1985. The Company provides freestanding, fixed-site outpatient diagnostic imaging services in the United States based on number of locations and annual imaging revenue. At December 31, 2012, it operated directly or indirectly through joint ventures, 250 centers located in California, Maryland, Florida, Delaware, New Jersey, Rhode Island and New York. Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. Diagnostic imaging involves the use of non-invasive procedures to generate representations of internal anatomy and function that can be recorded on film or digitized for display on a video monitor. Diagnostic imaging procedures facilitate the early diagnosis and treatment of diseases and disorders and may reduce unnecessary invasive procedures, often minimizing the cost and amount of care for patients. Diagnostic imaging procedures include MRI, CT, PET, nuclear medicine, ultrasound, mammography, X-ray and fluoroscopy. While X-ray remains the commonly performed diagnostic imaging procedure, the growing and higher margin procedures are MRI, CT and PET. The rapid growth in PET scans is attributable to the increasing recognition of the efficacy of PET scans in the diagnosis and monitoring of cancer. The number of MRI and CT scans performed annual in the United States continues to grow due to their wider acceptance by physicians and payors, an increasing number of applications for their use and a general increase in demand due to the aging population. The Company's sales and marketing team employs a multi-pronged approach to marketing, including physician, payor and sports marketing programs. The market for diagnostic imaging services is competitive. The Company competes locally with groups of radiologists, established hospitals, clinics and other independent organizations that own and operate imaging equipment. Its competitors include Alliance Healthcare Services, Inc., Diagnostic Imaging Group and several smaller regional competitors.

Ratios

vs
industry
vs
history
PE Ratio 40.33
RDNT's PE Ratio is ranked lower than
60% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.62 vs. RDNT: 40.33 )
Ranked among companies with meaningful PE Ratio only.
RDNT' s PE Ratio Range Over the Past 10 Years
Min: 1.44  Med: 21.98 Max: 961
Current: 40.33
1.44
961
PE Ratio without NRI 40.33
RDNT's PE Ratio without NRI is ranked lower than
60% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.50 vs. RDNT: 40.33 )
Ranked among companies with meaningful PE Ratio without NRI only.
RDNT' s PE Ratio without NRI Range Over the Past 10 Years
Min: 1.44  Med: 21.98 Max: 961
Current: 40.33
1.44
961
PB Ratio 5.81
RDNT's PB Ratio is ranked lower than
67% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. RDNT: 5.81 )
Ranked among companies with meaningful PB Ratio only.
RDNT' s PB Ratio Range Over the Past 10 Years
Min: 5.14  Med: 11.11 Max: 715.38
Current: 5.81
5.14
715.38
PS Ratio 0.32
RDNT's PS Ratio is ranked higher than
96% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. RDNT: 0.32 )
Ranked among companies with meaningful PS Ratio only.
RDNT' s PS Ratio Range Over the Past 10 Years
Min: 0.07  Med: 0.27 Max: 1.07
Current: 0.32
0.07
1.07
Price-to-Free-Cash-Flow 11.00
RDNT's Price-to-Free-Cash-Flow is ranked higher than
87% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.50 vs. RDNT: 11.00 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
RDNT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 1.59  Med: 11.36 Max: 161.28
Current: 11
1.59
161.28
Price-to-Operating-Cash-Flow 3.08
RDNT's Price-to-Operating-Cash-Flow is ranked higher than
97% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.60 vs. RDNT: 3.08 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
RDNT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 0.56  Med: 2.77 Max: 25.11
Current: 3.08
0.56
25.11
EV-to-EBIT 16.23
RDNT's EV-to-EBIT is ranked higher than
72% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. RDNT: 16.23 )
Ranked among companies with meaningful EV-to-EBIT only.
RDNT' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.3  Med: 17.8 Max: 44.7
Current: 16.23
9.3
44.7
EV-to-EBITDA 7.41
RDNT's EV-to-EBITDA is ranked higher than
92% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. RDNT: 7.41 )
Ranked among companies with meaningful EV-to-EBITDA only.
RDNT' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.1  Med: 7.3 Max: 16.3
Current: 7.41
5.1
16.3
Shiller PE Ratio 76.13
RDNT's Shiller PE Ratio is ranked lower than
80% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.15 vs. RDNT: 76.13 )
Ranked among companies with meaningful Shiller PE Ratio only.
RDNT' s Shiller PE Ratio Range Over the Past 10 Years
Min: 66.88  Med: 165.17 Max: 763
Current: 76.13
66.88
763
Current Ratio 1.40
RDNT's Current Ratio is ranked lower than
78% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. RDNT: 1.40 )
Ranked among companies with meaningful Current Ratio only.
RDNT' s Current Ratio Range Over the Past 10 Years
Min: 0.15  Med: 0.94 Max: 1.49
Current: 1.4
0.15
1.49
Quick Ratio 1.40
RDNT's Quick Ratio is ranked lower than
71% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. RDNT: 1.40 )
Ranked among companies with meaningful Quick Ratio only.
RDNT' s Quick Ratio Range Over the Past 10 Years
Min: 0.15  Med: 0.94 Max: 1.49
Current: 1.4
0.15
1.49
Days Sales Outstanding 67.76
RDNT's Days Sales Outstanding is ranked lower than
56% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. RDNT: 67.76 )
Ranked among companies with meaningful Days Sales Outstanding only.
RDNT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.13  Med: 71.6 Max: 80.12
Current: 67.76
61.13
80.12
Days Payable 19.27
RDNT's Days Payable is ranked lower than
83% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. RDNT: 19.27 )
Ranked among companies with meaningful Days Payable only.
RDNT' s Days Payable Range Over the Past 10 Years
Min: 14.67  Med: 23.65 Max: 28.38
Current: 19.27
14.67
28.38

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.10
RDNT's 3-Year Average Share Buyback Ratio is ranked higher than
54% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. RDNT: -5.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RDNT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -20.1  Med: -2.1 Max: 0.8
Current: -5.1
-20.1
0.8

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 1.16
RDNT's Price-to-Median-PS-Value is ranked lower than
59% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. RDNT: 1.16 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
RDNT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.34  Med: 0.74 Max: 3.1
Current: 1.16
0.34
3.1
Earnings Yield (Greenblatt) % 6.16
RDNT's Earnings Yield (Greenblatt) % is ranked higher than
84% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. RDNT: 6.16 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
RDNT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.2  Med: 5.6 Max: 10.8
Current: 6.16
2.2
10.8
Forward Rate of Return (Yacktman) % -7.59
RDNT's Forward Rate of Return (Yacktman) % is ranked lower than
85% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.75 vs. RDNT: -7.59 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
RDNT' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -12.2  Med: 3.65 Max: 24
Current: -7.59
-12.2
24

More Statistics

Revenue (TTM) (Mil) $884.5
EPS (TTM) $ 0.15
Beta1.53
Short Percentage of Float0.50%
52-Week Range $4.83 - 7.98
Shares Outstanding (Mil)47.20

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) 0.37
EPS without NRI ($) 0.37
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for RDNT

Headlines

Articles On GuruFocus.com
RadNet, Inc. Announces Date of its First Quarter 2017 Financial Results Conference Call Apr 28 2017 
Shin Imaging Center Implements eRAD Platform Apr 24 2017 
Adams Diagnostic Innovates with eRAD Technology Apr 21 2017 
Advanced Diagnostic Imaging Center Deploys eRAD Platform Apr 20 2017 
RadNet Announces Formation of Two Los Angeles-Area Joint Ventures With Cedars-Sinai Apr 03 2017 
Doral Financial Corp (DRL) Skyrockets with Unusual Market Activity, RadNet Inc (RDNT) Soars on Resul May 12 2014 
Weekly 3-Year Lows Highlight: FWM, FST, LAND, RDNT Jan 13 2014 
RadNet Inc. Reports Operating Results (10-K) Mar 11 2011 
RadNet Inc. Reports Operating Results (10-Q) Aug 09 2010 
RadNet Inc. (RDNT) Executive VP and CFO Mark Stolper sells 22,200 Shares Sep 22 2009 

More From Other Websites
RadNet, Inc. Announces Date of its First Quarter 2017 Financial Results Conference Call Apr 28 2017
Shin Imaging Center Implements eRAD Platform Apr 24 2017
Adams Diagnostic Innovates with eRAD Technology Apr 21 2017
Advanced Diagnostic Imaging Center Deploys eRAD Platform Apr 20 2017
ETFs with exposure to RadNet, Inc. : April 5, 2017 Apr 05 2017
RadNet Announces Formation of Two Los Angeles-Area Joint Ventures With Cedars-Sinai Apr 03 2017
RadNet, Inc. :RDNT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Mar 21 2017
Edited Transcript of RDNT earnings conference call or presentation 14-Mar-17 2:30pm GMT Mar 14 2017
RadNet posts 4Q profit Mar 14 2017
RadNet Reports Record Fourth Quarter and Full Year 2016 Results and Releases 2017 Financial Guidance Mar 14 2017
RadNet, Inc. Announces Date of its Fourth Quarter 2016 Financial Results Conference Call Mar 03 2017
RadNet Announces Amendment to First Lien Credit Facilities Feb 02 2017
RadNet, Inc. – Value Analysis (NASDAQ:RDNT) : December 27, 2016 Dec 27 2016
RadNet, Inc. breached its 50 day moving average in a Bullish Manner : RDNT-US : December 26, 2016 Dec 26 2016
Is Akebia Therapeutics Inc (AKBA) A Good Stock To Buy? Dec 17 2016
Is RadNet Inc. (RDNT) Going to Burn These Hedge Funds? Dec 13 2016
Edited Transcript of RDNT earnings conference call or presentation 9-Nov-16 3:30pm GMT Nov 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)